{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:27:41Z","timestamp":1785374861859,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014165","name":"PHARMAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000857","name":"Loughborough University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018517","name":"Office for National Statistics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018517","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jgar.2024.05.020","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T23:34:17Z","timestamp":1717025657000},"page":"306-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6473-8560","authenticated-orcid":false,"given":"Kailey","family":"Ben-Sassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-3236","authenticated-orcid":false,"given":"Suhail","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2024.05.020_bib0001","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7861\/clinmedicine.18-2-160","article-title":"Diagnosis and management of cellulitis","volume":"18","author":"Sullivan","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jgar.2024.05.020_bib0002","unstructured":"National Institute for Health and Care Excellence (NICE). NICE clinical knowledge summary: cellulitis \u2013 acute. https:\/\/cks.nice.org.uk\/topics\/cellulitis-acute\/background-information\/definition\/ [accessed 8 December 2021]."},{"key":"10.1016\/j.jgar.2024.05.020_bib0003","series-title":"Primary care antimicrobial guidelines","year":"2015"},{"key":"10.1016\/j.jgar.2024.05.020_bib0004","series-title":"Annual PEDW data tables: primary diagnosis (3-character detail), Welsh providers, 2019\/20","year":"2021"},{"key":"10.1016\/j.jgar.2024.05.020_bib0005","series-title":"Hospital episode statistics for England. Admitted patient care statistics, 2020-21","year":"2022"},{"key":"10.1016\/j.jgar.2024.05.020_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjd.17613","article-title":"Cellulitis: how can we know what patients don't know?","volume":"180","author":"Levell","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jgar.2024.05.020_bib0007","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/jac\/dky294","article-title":"Impact of the implementation of a nurse-managed outpatient parenteral antibiotic therapy (OPAT) system in Baltimore: a case study demonstrating cost savings and reduction in re-admission rates","volume":"73","author":"Mansour","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.020_bib0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7861\/clinmedicine.13-1-35","article-title":"Outpatient parenteral antimicrobial therapy in a changing NHS: challenges and opportunities","volume":"13","author":"Chapman","year":"2013","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jgar.2024.05.020_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejim.2013.03.014","article-title":"Outpatient parenteral antibiotic therapy: principles and practice","volume":"24","author":"Seaton","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jgar.2024.05.020_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049733","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses","volume":"11","author":"Dimitrova","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jgar.2024.05.020_bib0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2024.05.020_bib0012","unstructured":"ADVANZ PHARMA. Summary of product characteristics: Xydalba 500 mg powder for concentrate for solution for infusion. 2023. https:\/\/www.medicines.org.uk\/emc\/product\/2270\/smpc [accessed August 28, 2023]."},{"key":"10.1016\/j.jgar.2024.05.020_bib0013","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/antibiotics10091129","article-title":"Use of dalbavancin in skin, bone and joint infections: a real-life experience in an Italian center","volume":"10","author":"Brescini","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"10.1016\/j.jgar.2024.05.020_bib0014","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/acem.14258","article-title":"Pathway with single-dose long-acting intravenous antibiotic reduces emergency department hospitalizations of patients with skin infections","volume":"28","author":"Talan","year":"2021","journal-title":"Acad Emerg Med"},{"issue":"10","key":"10.1016\/j.jgar.2024.05.020_bib0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/antibiotics11101377","article-title":"Off-label use of dalbavancin for sequential treatment of spondylodiscitis by methicillin-resistant Staphylococcus aureus: a retrospective single-centre experience","volume":"11","author":"Mazzitelli","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.jgar.2024.05.020_bib0016","doi-asserted-by":"crossref","first-page":"dlab099","DOI":"10.1093\/jacamr\/dlab099","article-title":"Use of dalbavancin in infective endocarditis: a case series","volume":"3","author":"Guleri","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2024.05.020_bib0017","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/jamadermatol.2018.4650","article-title":"Analysis of readmissions following hospitalization for cellulitis in the United States","volume":"155","author":"Fisher","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jgar.2024.05.020_bib0018","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dky400","article-title":"Association of the Dundee severity classification with mortality, length of stay and readmission in adult inpatients with cellulitis","volume":"74","author":"Cutfield","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2024.05.020_bib0019","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jhin.2020.12.027","article-title":"Bed-days and costs associated with the inpatient burden of healthcare-associated infection in the UK","volume":"114","author":"Manoukian","year":"2021","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jgar.2024.05.020_bib0020","series-title":"Less reliance on hospitals & more care closer to home \u2013 health secretary outlines revolution in Wales\u2019 health & social care","year":"2018"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716524001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T09:41:51Z","timestamp":1726393311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716524001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"alternative-id":["S2213716524001085"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.020","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2024.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}